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Abstract
Background: Fatty liver is known to be linked with insulin resistance, alcohol intake, diabetes and obesity. Biopsy and 
even scan-assessed fatty liver are not always feasible in clinical practice. This report evaluates the predictive ability of 
two recently published markers of fatty liver: the Fatty Liver Index (FLI) and the NAFLD fatty liver score (NAFLD-FLS), for 
9-year incident diabetes, in the French general-population cohort: Data from an Epidemiological Study on the Insulin 
Resistance syndrome (D.E.S.I.R).
Methods: At baseline, there were 1861 men and 1950 women, non-diabetic, aged 30 to 65 years. Over the follow-up, 
203 incident diabetes cases (140 men, 63 women) were identified by diabetes-treatment or fasting plasma glucose ≥ 
7.0 mmol/l. The FLI includes: BMI, waist circumference, triglycerides and gamma glutamyl transferase, and the NAFLD-
FLS: the metabolic syndrome, diabetes, insulin, alanine aminotransferase, and asparate aminotransferase. Logistic 
regression was used to determine the odds ratios for incident diabetes associated with categories of the fatty liver 
indices.
Results: In comparison to those with a FLI < 20, the age-adjusted odds ratio (95% confidence interval) for diabetes for 
a FLI ≥ 70 was 9.33 (5.05-17.25) for men and 36.72 (17.12-78.76) for women; these were attenuated to 3.43 (1.61-7.28) 
and 11.05 (4.09 29.81), after adjusting on baseline glucose, insulin, hypertension, alcohol intake, physical activity, 
smoking and family antecedents of diabetes; odds ratios increased to 4.71 (1.68-13.16) and 22.77 (6.78-76.44) in those 
without an excessive alcohol intake. The NAFLD-FLS also predicted incident diabetes, but with odds ratios much lower 
in women, similar in men.
Conclusions: These fatty liver indexes are simple clinical tools for evaluating the extent of liver fat and they are 
predictive of incident diabetes. Physicians should screen for diabetes in patients with fatty liver.
Background
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver injury in Western coun-
tries and about 20 to 30% of people with NAFLD have
non alcoholic steatohepatitis (NASH), which is associated
with fibrosis and can progress to cirrhosis, terminal liver
failure and hepatocellular carcinoma [1]. The obese, the
insulin resistant and the diabetic patient have a higher
prevalence of NAFLD [2], and metabolic steatosis may be
a major risk factor for disease progression. A liver biopsy
is the only way to reliably diagnose NAFLD, but even this
technique is not 100% precise due to the sampling vari-
ability of biopsies. Clearly a biopsy is very invasive and
carries a risk, thus proxy markers are often used [3].
However while the extent of liver fat correlates with liver
enzymes: alanine aminotransferase (ALT), asparate amin-
otransferase (AST), gamma glutamyl transferase (GGT),
there are other commonly measured factors such as obe-
sity which are also associated. Thus to aid in screening for
fatty liver, Bedogni et al. [4], developed a simple score,
from a cohort of patients with suspected liver disease and
a group of controls. Their Fatty Liver Index (FLI) uses an
equation with GGT, triglycerides, body mass index (BMI)
and waist circumference. Another score has recently been
published by a Finnish group [5,6], the NAFLD fatty liver
score (NAFLD-FLS). This includes in its definition, the
presence of diabetes, the metabolic syndrome, and levels
of ALT, AST and fasting insulin.
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Page 2 of 9Cross-sectional studies have shown that fatty liver and
metabolic abnormalities, including insulin resistance and
diabetes, occur together [7]. We have recently shown, in a
cross-sectional study, that the FLI is positively associated
with insulin resistance, coronary risk and with an
increased intima-media thickness [8]. It is generally
thought that insulin resistance precedes the development
of fatty liver, but the evidence is not conclusive, and it has
been proposed that fatty liver is pathogenetically involved
in the emergence of insulin resistance and type 2 diabetes
[9].
A number of prospective studies have shown that eleva-
tions in liver enzymes ALT and GGT precede the devel-
opment of diabetes [10,11]. Whether NAFLD precedes
diabetes, using a more precise evaluation of NAFLD, has
been much less studied. In a cohort of Korean adults,
fatty liver, as assessed by ultrasound, was predictive of
diabetes, particularly moderate to severe fatty liver, after
adjusting for other diabetes risk factors [12]. In a 4-year
prospective Chinese case-control study in which NAFLD
was evaluated by ultrasound, it was shown that NAFLD
preceded metabolic disorders, independently of obesity
[13]. To our knowledge, there is no large study which has
specifically assessed whether fatty liver indices predict
type 2 diabetes.
We study in a prospective context, whether the Fatty
Liver Index and the NAFLD fatty liver score are able to
predict incident diabetes in a large French cohort, fol-
lowed over a 9-year period. We studied men and women
separately to evaluate whether the relations were consis-
tent.
Methods
Study population
The study population was men and women aged 30-65
years, who participated in the 9 year follow-up study,
Data from an Epidemiological Study on the Insulin Resis-
tance syndrome (D.E.S.I.R.). Participants were recruited
from volunteers offered periodic health examinations
free of charge by the French Social Security, in 10 health
examination centres in western France [14]. All partici-
pants signed an informed consent and the protocol was
approved by the ethics committee of the Kremlin Bicêtre
Hospital, Kremlin Bicêtre, France.
Incident cases of diabetes were identified by treatment
for diabetes or a fasting plasma glucose ≥ 7.0 mmol/l, at
one of the four, three-yearly examinations, after exclusion
of individuals with diabetes at baseline and those with
unknown diabetic status at the 9-year examination. We
study the 1861 men and 1950 women who had data avail-
able at baseline on glucose, triglycerides, BMI, GGT,
waist circumference and known diabetes status at the 9-
year examination. For the calculation of the NAFLD-FLS,
data is available for 1848 men and 1940 women.
Measures at inclusion
Two measures of blood pressure, using a mercury sphyg-
momanometer, and two measures of heart rate were
taken in a supine position after participants had rested
during 5 minutes; mean values were used. Weight and
height were measured on lightly clad participants, and
BMI calculated. The waist circumference, the smallest
circumference between the lower ribs and the iliac crests,
was also measured.
The examining physician recorded treatment for diabe-
tes, hypertension and lipids and whether participants had
diabetes in their family; for women, they also recorded
whether they had a baby over 4 kg and their menopausal
status. Hypertension was defined by systolic/diastolic
blood pressures of at least 140/90 mmHg or being on
antihypertensive medication. Smoking habits (current
smoker or not), alcohol consumption (gram per day of
alcohol from wine, beer, cider, spirits) and degree of phys-
ical activity (at home, at work and sport, each one coded
on a four level scale) were assessed using a self-adminis-
tered questionnaire. Intense physical activity was coded if
an individual had a score of four on any of the three items
(at home, at work or sport), or a score of 3 for sporting
activity and 3 for physical activity either at home or at
work.
All biochemical measurements were from one of four
health-centre laboratories located in France at Blois,
Chartres, La Riche or Orléans. Fasting plasma glucose,
measured by the glucose-oxidase method, was applied to
fluoro-oxalated plasma using a Technicon RA100 (Bayer
Diagnostics, Puteaux, France) or a Specific or a Delta
device (Konelab, Evry, France). Total cholesterol, HDL-
cholesterol, triglycerides, ALT, AST, GGT, and creatinine
were assayed by DAX 24 (Bayer Diagnostics, Puteaux,
France) or KONE (Evry, France). Insulin was quantified
by micro particle enzyme immunoassay with an auto-
mated analyzer IMX (Abbott, Rungis, France). White cell
counts were determined by a Technicon H* or a Techni-
con H3RTX (Bayer Diagnostics, Puteaux, France) or a
JT2 (Beckman/Coulter, Roissy, France) or an Argos (ABX,
Montpellier, France). The inter-laboratory variability was
assessed monthly on normal and pathological values for
each biologic variable.
Surrogate Measures of Fatty Liver
The FLI score was developed by logistic regression using
data from a population of individuals, 216 with and 280
without suspected liver disease [4]. The presence of fatty
liver was identified using ultrasound, and defined accord-
ing to a brightness scale. The score runs from 0 and 100
and estimates the percentage chance of having a fatty
liver:
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Page 3 of 9with triglycerides measured in mg/dl, GGT in IU/l and
waist circumference in cm. All four factors contributed
about equally to this score when converted to Z-scores.
The more recently published NAFLD Fatty Liver Score
[5,6], was developed from a Finish population which
included 359 non diabetic and 111 type 2 diabetic indi-
viduals; liver fat content was measured by proton mag-
netic resonance spectroscopy and NAFLD was defined to
be present when there was at least 55.6 mg triglyceride
per g. of liver tissue. The NAFLD-FLS equation is the lin-
ear function derived from logistic regression, and so
could be converted to a percent chance of fatty liver, in
the same form as the equation above. We retain the form
of the equation as published:
with insulin measured in mU/l and AST and ALT in U/
L. The International Diabetes Federation (IDF) definition
of the metabolic syndrome is [15]: central obesity (waist
circumference ≥ 94 cm in men, ≥ 80 cm in women) and at
least two of the following factors: (1) triglycerides ≥ 1.70
mmol/l or specific treatment for this lipid abnormality;
(2) HDL-cholesterol < 1.03 mmol/l in men and < 1.29
mmol/l in women or specific treatment for this lipid
abnormality; (3) systolic blood pressure ≥ 130 mm Hg or
diastolic blood pressure ≥ 85 mm Hg or treatment for
previously diagnosed hypertension; (4) fasting plasma
glucose ≥ 5.6 mmol/L or previously diagnosed type 2 dia-
betes. As we did not know whether lipid treatment was
specific for HDL-cholesterol or for triglycerides, we did
not include this in our definition. In our population, as we
studied incident diabetes, there were no individuals with
diabetes at baseline, so the term in type 2 diabetes does
not contribute to the NAFLD-FLS in our study.
Statistical methods
Analyses used SAS Version 9.1 (SAS Institute Inc. Cary,
NC USA). BMI, fasting glucose, insulin, ALT, AST, GGT,
triglycerides and white blood cell count were log-trans-
formed for statistical analysis, because of their skewed
distributions. Hypertension (HTA) was defined by a sys-
tolic blood pressure ≥ 140 mmHg and/or a diastolic blood
pressure ≥ 90 mmHg and/or an antihypertensive treat-
ment.
The characteristics of the men and women, according
to FLI classes, are shown as means ± SD or numbers (per-
centages), which we compared using ANOVA or logistic
regression, after adjusting for age. Spearman correlation
coefficients were used to describe associations.
Logistic regression models were used to predict 9-year
incident diabetes from three categories of the FLI, with
adjustment for diabetes risk factors: age, glucose, insulin,
physical activity, smoking, alcohol, diabetes in the family,
and HTA. A trend test was used to compare the odds
ratios across the three FLI categories, with the categories
were coded as 1, 2 and 3. A secondary analysis compared
the odds ratios in those without an excessive alcohol
intake: < 30 g/day in men and < 20 g/day in women. To
compare the two fatty liver indices, odds ratios for inci-
dent diabetes were also compared across quartiles of the
indices, with and without adjustment for the above diabe-
tes risk factors. The difference in odds ratios between
men and women was tested by the inclusion of an inter-
action term between sex and each index. The data was
further grouped to compare individuals in the upper
quartile group and the three lower quartile groups, to
decrease the width of the confidence intervals of the odds
ratios, as there were few incident diabetes cases in the
lowest quartile group. The c-statistic and the model
goodness-of-fit Hosmer-Lemeshow tests were evaluated
for the two indices, and compared with the predictive
model for incident diabetes that we have already pub-
lished [16]. The D.E.S.I.R. diabetes risk score includes, for
men: waist circumference, smoking, fasting glucose and
GGT, and for women: BMI, diabetes in the family, fasting
glucose and triglycerides.
Results
Characteristics of the study population according to the 
Fatty Liver Index
As expected, the distribution of the FLI differed between
men and women, with fewer women having a high FLI.
The elements included in the FLI: triglycerides, BMI,
GGT and waist circumference were clearly related with
the FLI in both men and women (Table 1). Incident dia-
betes increased across the FLI groups, P < 0.0001 for both
men and women, and despite the small numbers of inci-
dent cases, the three-yearly incidences also increased
across FLI groups. The relation between FLI and diabetes
in the family was not statistically significant, but with few
exceptions, cardio-metabolic risk factors and liver
enzymes were strongly associated with the FLI. Lack of
intense physical activity and smoking were also related
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Page 4 of 9Table 1: Means ± SD and n (%) of clinical and biological variables associated with incident diabetes, according to values of the Fatty Liver 
Index of < 20, 20-69, ≥ 70 at baseline; The D.E.S.I.R. Study.
Men Women
Fatty Liver Index P-valuesa Fatty Liver Index P-valuesa
< 20 20-69 ≥ 70 < 20 20-69 ≥ 70
n = 594 
(32%)
n = 990 
(53%)
n = 277 
(15%)
n = 1430 
(73%)
n = 445 (23%) n = 75 (4%)
Incident diabetes years 
0 to 9
14 (2) 69 (7) 57 (21) 0.0001 13 (1) 30 (7) 20 (27) 0.0001
years 0 to 3 5 (1) 21 (2) 26 (10) 0.0001 7 (1) 14 (3) 9 (13) 0.0001
years 3 to 6b 3 (1) 18 (2) 16 (7) 0.0001 1 (0.1) 4 (1) 6 (10) 0.0001
years6 to 9c 6 (1) 25 (3) 11 (5) 0.005 5 (0.3) 10 (2) 5 (8) 0.0001
Diabetes in family 102 (17) 178 (18) 59 (21) 0.07 274 (19) 104 (23) 17 (23) 0.1
Age (years) 43 ± 10 48 ± 10 50 ± 9 0.0001 46 ± 10 52 ± 9 51 ± 9 0.0001
Waist circumference 
(cm)
81 ± 5 91 ± 6 102 ± 7 0.0001 72 ± 6 87 ± 7 101 ± 8 0.0001
BMI (kg/m2) 22.5 ± 1.8 25.7 ± 2.0 29.6 ± 2.9 0.0001 22.2 ± 2.3 27.7 ± 2.9 33.4 ± 4.2 0.0001
Glucose (mmol/l) 5.3 ± 0.5 5.5 ± 0.5 5.7 ± 0.6 0.0001 5.0 ± 0.4 5.3 ± 0.5 5.6 ± 0.5 0.0001
HbA1c (%) 5.4 ± 0.4 5.5 ± 0.4 5.6 ± 0.4 0.0001 5.3 ± 0.4 5.5 ± 0.4 5.7 ± 0.5 0.0001
Insulin (pmol/l) ‡ 33 ± 14 49 ± 24 74 ± 44 0.0001 37 ± 16 58 ± 29 90 ± 44 0.0001
Menopause 453 (32) 251 (57) 42 (56) 0.7
Large baby > 4 kg 190 (14) 91 (21) 19 (27) 0.0001
Treatment for HTA 15 (3) 102 (10) 51 (18) 0.0001 105 (7) 95 (21) 25 (33) 0.0001
Systolic BP (mmHg) 128 ± 12 135 ± 14 142 ± 16 0.0001 125 ± 14 135 ± 16 141 ± 18 0.0001
Diastolic BP (mmHg) 78 ± 8 82 ± 9 87 ± 10 0.0001 76 ± 8 82 ± 9 83 ± 8 0.0001
Heart rate (min) 64 ± 10 66 ± 9 70 ± 11 0.0001 68 ± 9 69 ± 10 72 ± 12 0.0001
Treatment for lipids 22 (4) 90 (9) 33 (12) 0.005 75 (5) 53 (12) 10 (13) 0.2
Triglycerides (mmol/l)d 0.79 ± 0.30 1.36 ± 0.74 2.20 ± 1.25 0.0001 0.79 ± 0.35 1.30 ± 0.57 1.88 ± 0.81 0.0001
HDL-cholesterol 
(mmol/l) d
1.64 ± 0.41 1.44 ± 0.35 1.33 ± 0.31 0.0001 1.86 ± 0.42 1.63 ± 0.39 1.47 ± 0.30 0.0001
Cholesterol (mmol/l) 5.43 ± 0.85 5.92 ± 0.93 6.39 ± 1.07 0.0001 5.47 ± 0.91 6.01 ± 0.99 6.26 ± 1.02 0.0001
GGT (IU/l) d 22.2 ± 11.4 40.4 ± 28.1 85.9 ± 76.4 0.0001 17.6 ± 10.9 30.8 ± 23.8 58.8 ± 68.3 0.0001
ALT (IU/l) d 22.8 ± 8.5 32.2 ± 19.3 45.4 ± 25.4 0.0001 17.9 ± 8.3 26.4 ± 22.9 31.4 ± 20.7 0.0001
AST (IU/l) d 20.4 ± 6.3 23.2 ± 11.0 27.8 ± 15.5 0.0001 17.3 ± 6.8 20.4 ± 13.6 21.4 ± 11.2 0.0001
Creatinine (μmol/l) 87.2 ± 10.4 89.9 ± 11.1 91.1 ± 13.2 0.0001 73.7 ± 9.6 75.2 ± 10.8 78.8 ± 12.3 0.0001
White Blood Cell
count (104/mm3) d
62 ± 17 65 ± 17 66 ± 17 0.0001 61 ± 16 65 ± 15 74 ± 36 0.0001
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Page 5 of 9with the FLI, but for alcohol intake, a positive relation
was only clear in the men. The presence of the IDF meta-
bolic syndrome and the mean value of the NAFLD-FLS
increased with increasing FLI. The Spearman correlation
coefficients between the FLI and the NAFLD FLS were
0.70 in men and 0.64 in women.
Relation between incident diabetes and the Fatty Liver 
Index
The unadjusted odds ratios (95% confidence intervals) for
incident diabetes were in men: 10.73 (5.86-19.66) and
3.10 (1.73-5.56) for FLI ≥ 70 and between 20 and 69,
respectively, in comparison to men with a FLI < 20; for
women, the corresponding odds ratios were 39.64 (18.75-
83.78) and 7.88 (4.07 15.24) (Table 2). These odds ratios
were slightly attenuated after adjustment for age, and
then additionally after separate adjustment for, glucose,
insulin, physical activity, smoking, alcohol intake, diabe-
tes in the family, and hypertension. After multivariate
adjustment for all of these factors, there was a trend
across the three FLI categories. In comparison to those
with an FLI < 20, men with a FLI ≥ 70 had an odds ratio
for incident diabetes of 3.43 (1.61-7.28), and women
11.05 (4.09-29.81). For the middle group with an FLI of
20-69, the odds ratios differed from 1, and were of the
order of two in men and three in women.
Relations in the population without an excessive alcohol 
intake
When the analyses were restricted to men with an alcohol
intake < 30 g/day and women with an intake < 20 g/day,
the fully adjusted odds ratios for incident diabetes in
those with an FLI ≥ 70 were increased to 4.71 (1.68-13.16)
in men and 22.77 (6.78-76.44) in women, in comparison
to men or women with a FLI < 20. (Table 2).
Comparing the predictive power of the Fatty Liver Index 
and the NAFLD Fatty Liver Score
To compare these two fatty liver incides, the population
was divided into sex-specific quartiles for each index. The
unadjusted odds ratios showed that both the FLI and the
NAFLD-FLS were highly predictive of incident diabetes
(Table 3). In comparison to the first quartile group, the
last quartile group of the FLI carried odds ratios of 11.69
(5.58-6.74) in men and 54.40 (7.49-395) in women; for the
NAFLD-FLS the odds were 9.47 (4.84-18.52) and 27.13
(6.56-112) respectively. After adjustment on diabetes risk
factors, the odds ratios for incident diabetes increased
across the quartiles, with the odds ratios for last quartile
groups higher than the odds ratios for the first quartile
groups, which were chosen as the reference groups. Com-
paring the highest quartile group of these indices with the
group including individuals in the three lower quartile
groups, after adjustment for other factors associated with
incident diabetes, the two indices provided similar odds
ratios - for men of the order of 2, and for women, 4. How-
ever, the odds ratios did not differ statistically between
men and women, (FLI: P = 0.2 and NAFLD-FLS: P = 0.1).
The fully adjusted FLI provided a reasonable discrimi-
nation of cases and non-cases of incident diabetes, with
c-statistics of 0.74 in men and 0.84 in women and for the
NAFLD-FLS the c-statistics were 0.74 and 0.83, respec-
tively; the models provided a reasonable fit according to
the Hosmer-Lemeshow test, with all tests non-signifi-
cant.
As expected, the models we have already published,
which included the best combination of clinical and bio-
logical factors to predict diabetes, had higher c-statistic
values, 0.85 in men and 0.92 in women. The fatty liver
indices and the D.E.S.I.R. diabetes score screen different
high risk individuals: those with a high score from the
Intense physical 
activity
180 (30) 193 (19) 40 (14) 0.0001 318 (22) 64 (14) 12 (16) 0.01
Smoker 155 (26) 240 (24) 75 (27) 0.03 200 (14) 47 (11) 12 (16) 0.03
Alcohol (g/day) 18 ± 20 25 ± 22 36 ± 29 0.0001 7 ± 11 8 ± 13 9 ± 14 0.8
≥ 30/20g/day men/
women
143 (24) 315 (32) 133 (48) 0.0001 363 (25) 125 (28) 23 (31) 0.7
IDF metabolic 
syndrome
0 (0) 162 (17) 193 (71) 0.0001 23(2) 152 (34) 52 (69) 0.0001
NAFLD Fatty Liver 
Score (5)
-2.34 ± 0.44 -1.57 ± 0.89 -0.14 ± 1.31 0.0001 -2.44 ± 0.57 -1.34 ± 1.06 -0.13 ± 1.21 0.0001
a p-values from ANOVA or logistic regression, adjusted on age
b 4 individuals with unknown diabetic status at 3 years of follow-up
c 7 individuals with unknown diabetic status known at 6 years of follow-up
d log-transformation for analysis because of a non-symmetric distribution
Table 1: Means ± SD and n (%) of clinical and biological variables associated with incident diabetes, according to values of the Fatty Liver 
Index of < 20, 20-69, ≥ 70 at baseline; The D.E.S.I.R. Study. (Continued)
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Table 2: Odds ratios (95% confidence intervals) for incident diabetes, with P values for trend across baseline Fatty Liver 
Index classes; The D.E.S.I.R. Study.
MEN
Fatty Liver Index P - value 
trend
Adjustment factors < 20 20-69 ≥ 70
n = 594 n = 990 n = 277
Not adjusted 1 3.10 (1.73-5.56) 10.73 (5.86-19.65) 0.0001
Age 1 2.77 (1.54-5.01) 9.33 (5.05-17.25) 0.0001
Age + glucose 1 2.39 (1.28-4.45) 6.09 (3.17-11.70) 0.0001
Age + insulin ‡ 1 1.85 (1.00-3.42) 4.28 (2.15-8.50) 0.0001
Age + physical activity 1 2.76 (1.53-5.00) 9.27 (5.00-17.19) 0.0001
Age + smoking 1 2.73 (1.51-4.93) 9.02 (4.87-16.71) 0.0001
Age + alcohol 1 2.65 (1.47-4.80) 8.15 (4.36-15.23) 0.0001
Age + diabetes in family 1 2.77 (1.53-5.00) 9.27 (5.01-17.15) 0.0001
Age + hypertension (HTA) 1 2.58 (1.42-4.68) 7.96 (4.25-14.93) 0.0001
Age + alcohol, glucose, insulin, physical activity, smoking, 
diabetes in family, HTA
1 1.92 (1.00-3.66) 3.43 (1.61-7.28) 0.0009
Where alcohol < 30 g/day n = 451 n = 675 n = 144
Age 1 3.65 (1.69-7.86) 9.49 (4.12-21.85) 0.0001
Age + alcohol, glucose, insulin, physical activity, smoking, 
diabetes in family, HTA
1 2.72 (1.16-6.38) 4.71 (1.68-13.16) 0.003
WOMEN
Fatty Liver Index P -value 
trend
Adjustment factors < 20 20-69 ≥ 70
n = 
1430
n = 445 n = 75
Not adjusted 1 7.88 (4.07-15.24) 39.64 (18.75-83.78) 0.0001
Age 1 7.21 (3.64-14.28) 36.72 (17.12-78.76) 0.0001
Age + glucose 1 3.79 (1.84-7.77) 13.60 (5.92-31.24) 0.0001
Age + insulin ‡ 1 4.65 (2.22-9.72) 15.49 (6.17-38.85) 0.0001
Age + physical activity 1 7.08 (3.57-14.06) 36.06 (16.78-77.48) 0.0001
Age + smoking 1 7.12 (3.59-14.11) 35.70 (16.62-76.68) 0.0001
Age + alcohol 1 7.23 (3.65-14.33) 37.13 (17.28-79.78) 0.0001
Age + diabetes in family 1 6.87 (3.45-13.70) 37.87 (17.45-82.17) 0.0001
Age + hypertension (HTA) 1 6.42 (3.21-12.85) 29.24 (13.22-64.68) 0.0001
Age + alcohol, glucose, insulin, physical activity, smoking, 
diabetes in family, HTA
1 3.27 (1.49-7.20) 11.05 (4.09-29.81) 0.0001
Where alcohol < 20 g/day n = 1067 n = 320 n = 52
Age 1 9.79 (4.02-23.85) 66.84 (25.70-173.88) 0.0001
Age + alcohol, glucose, insulin, physical activity, smoking, 
diabetes in family, HTA
1 4.38 (1.62-11.83) 22.77 (6.78-76.44) 0.0001
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Page 7 of 9D.E.S.I.R. risk score have higher glucose and HbA1c lev-
els but have less adiposity, lower liver function tests and
lower insulin levels than those at high risk according to
the FLI and the NAFLD-FLS indices.
Discussion
These two fatty liver indices were both predictive of inci-
dent diabetes, after adjusting for other known risk factors
of diabetes, including the most predictive factor, fasting
glucose at baseline. For the 15% of men with a FLI > 70,
the multivariate adjusted odds ratio for incident diabetes
was over three and for the 4% of women, the odds ratio
was over ten, however, this difference was not statistically
significant. In people with moderate alcohol intake, the
odds ratios were higher. While the individual factors in
the FLI - GGT, triglycerides, waist circumference and
BMI - have all been shown to be related with incident dia-
betes in our cohort [16], this specific linear combination
of diabetes risk factors, reflecting fatty liver, is also related
with incident diabetes. Equally, the NAFLD-FLS also pre-
dicted incident diabetes in both sexes. Again, most of the
individual parameters in this score are predictors of inci-
dent diabetes in univariate analysis in our cohort [16], the
exception being AST/ALT which we have not studied.
In the Korean study of 5372 individuals [12], of whom
68% were men, the relative risk of 5-year incident diabe-
tes in ultrasound diagnosed fatty liver, in comparison
with those without fatty liver, was 2.3 (1.1 4.7) in the 9%
of the population with moderate to severe fatty liver, and
1.5 (0.8-2.8) in the 21% with mild fatty liver, after adjust-
ment for other diabetes risk factors, including baseline
fasting glucose. It is not clear whether the authors
adjusted for alcohol intake, as it is not indicated in the
tables, only in the text in the Discussion section. In this
report, the authors did not analyse the predictive value of
fatty liver separately in men and women. A Chinese case-
control study [13] also showed that people with ultra-
sound-diagnosed NAFLD had a diabetes incidence of
20% in comparison to 5% in those without NAFLD; more
than 90% of participants in this study were men. Other
studies with smaller series of NAFLD patients have also
shown that a fatty liver is predictive of later diabetes
[17,18], however these studies must be interpreted with
caution, as there was no control group. In contrast, in a
large population of American veterans, of whom 98%
were men, diabetes at baseline was related with NAFLD
ten years later [19]. As the prevalent cases of NAFLD
were included in the analysis, the time sequence of
NAFLD and diabetes cannot be determined from this
study [19].
One of the proposed mechanisms for the relation
between fatty liver and insulin resistance is hepatic 'fat-
overflow', which leads to lipid accumulation and then to
hepatic insulin resistance followed by overall insulin
resistance [7]. It has been shown in a cross sectional study
in the Pima Indian population, that GGT and ALT activi-
ties were inversely correlated with both peripheral and
hepatic insulin sensitivity, as evaluated by a hyperinsuli-
naemic, euglycaemic clamp [20]. Another hypothesis is
that insulin resistance is invoked by an adipo-cytokine
imbalance, which then leads on to NAFLD [7]. Diabetes
and insulin resistance could develop at the same time as
NAFLD. Comparing the logistic regression models from
our study, adjusted on age and then age and insulin, there
was a reduction in the odds ratios for incident diabetes
associated with a high FLI ≥ 70 from 9.33 to 4.28 in men,
and from 36.72 to 15.49 in women, still significantly
higher than in the group with FLI < 20. Thus the relation
was attenuated, but not fully accounted for, by high insu-
lin levels. A higher FLI may reflect enhanced hepatic glu-
coneogenesis, which is known to contribute to the
pathophysiology of dysglycemia. The FLI may be viewed
as an indirect marker of impaired insulin secretion, one
of the major determinants of incident diabetes [21]. Early
interactions between beta cells and the liver need further
study.
We must acknowledge the limitation of using indices of
fatty liver in our study, as we did not have access to scan-
ning devices. In large epidemiologic studies, such tech-
niques are rarely available. The FLI has been developed
using ultrasound, the NAFLD-FLS by proton magnetic
resonance spectroscopy, whereas biopsy is the gold stan-
dard. Both scores can be criticised, and in particular the
NAFLD-FLS includes a large number of correlated items
as the metabolic syndrome is included, as well as diabetes
and insulin, and also both AST and AST/ALT. Further,
the populations on which these two studied indices were
developed are particular populations: for the FLI, 50% of
the individuals had suspected liver disease, and for the
NAFLD-FLS, one quarter of the individuals had diabetes.
These selection criteria led to average BMIs of 27 kg/m2
and over 30 kg/m2, for the populations in which the FLI
and the NAFLD-FLS were developed; the average BMI is
close to 25 kg/m2 in our French study. We are not able to
evaluate the sensitivity, specificity and predictive values
of either of these fatty liver indices in our general French
population, as we do not have a precise evaluation of fatty
liver. The strengths of our study include the large size of
the study population, the fact that it is a general popula-
tion not selected for particular characteristics, the long
nine year follow-up and the concordant results in both
men and women.
Conclusions
The novel finding of our study is that these two recently
published indices of liver fat are predictive of diabetes in
both men and women. The association was independent
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Table 3: Odds ratios (95% confidence intervals) for incident diabetes, across sex specific quartile groups of Fatty Liver 
Index and NAFLD fatty liver at baseline; The D.E.S.I.R. Study.
MEN no adjustment with adjustment*
diabetics/n OR (95% CI) P OR (95% CI) P
Fatty Liver Index
< 15.52 8/466 1 1
15.52 - 33.38 23/464 2.99 [1.32 - 6.74] 0.008 1.92 [0.81 - 4.56] 0.1
33.39 - 57.67 30/465 3.95 [1.79 - 8.71] 0.0007 2.17 [0.92 - 5.11] 0.07
> 57.67 79/466 11.69 [5.58 - 24.48] 0.0001 3.89 [1.65 - 9.14] 0.002
Fatty Liver Index
≤ 57.67 61/1395 1 1
>57.67 79/466 4.46 [3.14 - 6.35] 0.0001 2.04 [1.30 - 3.20] 0.002
NAFLD fatty liver score
< -2.34 10/462 1 1
-2.34 - -1.94 22/462 2.26 [1.06 - 4.83] 0.03 1.97 [0.88 - 4.37 ] 0.1
-1.93 - -1.15 25/462 2.59 [1.23 - 5.45] 0.01 2.05 [0.94 - 4.51 ] 0.07
> -1.15 80/462 9.47 [4.84 - 18.52] 0.0001 3.98 [1.93 - 8.20] 0.0002
NAFLD fatty liver score
≤ -1.15 57/1386 1 1
> -1.15 80/462 4.88 [3.41 - 6.99] 0.0001 2.32 [1.53 - 3.50] 0.0001
WOMEN no adjustment with adjustmenta
diabetics/n OR (95% CI) P OR (95% CI) P
Fatty Liver Index
< 3.78 1/488 1 1
3.78 - 7.64 4/487 4.03 [0.45 - 36.12] 0.2 3.51 [0.38 - 32.13] 0.3
7.65 - 21.64 9/488 9.14 [1.15 - 72.30] 0.04 4.09 [0.49 - 33.92] 0.2
> 21.64 49/487 54.40 [7.49 - 395] 0.0001 12.78 [1.59 - 102] 0.02
Fatty Liver Index
≤ 21.64 14/1463 1 1
> 21.64 49/487 11.58 [6.33 - 21.17] 0.0001 3.78 [1.79 - 7.95] 0.0005
NAFLD fatty liver score
< -2.65 2/486 1 1
-2.65 - -2.33 7/487 3.53 [0.73 - 17.07] 0.1 2.81 [0.57 - 13.92 ] 0.2
-2.32 - -1.82 4/487 2.00 [0.37 - 10.99] 0.4 1.17 [0.20 - 6.71 ] 0.9
> - 1.82 49/486 27.13 [6.56 - 112] 0.0001 6.58 [1.48 - 29.26] 0.01
NAFLD fatty liver score
≤ -1.82 13/1460 1 1
> - 1.82 49/486 12.48 [6.71 - 23.22] 0.0001 3.95 [1.93 - 8.07] 0.0002
a adjusted for age, glucose, insulin, physical activity, smoker, alcohol, diabetes in family, HTA; the NAFLD-FLS is not adjusted for insulin as 
insulin is already included in the NAFLD-FLS index
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diabetes in the family, insulin, sedentarity, smoking and
alcohol consumption, suggesting the clinical interest of
these indices to better identify patients consulting hepa-
tologists, who are at high risk of progression to diabetes.
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